Unmet Medical Need:  More than 300,000 breast cancer patients are diagnosed annually in the United States, and a significant subset experience cancer progression and/or recurrence. Such patients account for the ~40,000 annual deaths from the disease and impose substantial financial burden on the healthcare system.

Envisioned Healthcare Product:  OncoShell is a functional test that evaluates patient-specific drug response rapidly at low cost to guide chemotherapeutic treatment to reduce the number of patients with progression. Additional target markets include patients with other carcinomas.

Stage of Development: Validation

January 2017 Article

Awarded the AVON Breast Cancer Pilot Award, Herbert Irving Comprehensive Cancer Center in January 2018

Collaborative Research Team: Laura Kaufman, PhD; Asja Guzman, PhD; and Kevin Kalinsky, MD

Funding Cycle: 2017-2018